Integrating ESR1 Mutation Testing into Oncology Practices

ESR1 mutations play a significant role in endocrine resistance in hormone receptor-positive, HER2-negative metastatic breast cancer. These mutations allow estrogen receptor alpha (ERα) to remain active, even in the presence of endocrine therapy, leading to disease progression. Identifying ESR1 mutations through testing is a critical step in optimizing treatment strategies and improving patient outcomes.

Despite its importance, the implementation of ESR1 mutation testing varies across practice settings. Addressing these disparities requires increased collaboration among oncologists, pharmacists, and the entire care team.

This NCODA white paper examines the integration of ESR1 mutation testing across different oncology practice settings. Discover actionable insights and best practices to enhance ESR1 testing adoption and improve patient outcomes.

Read Report